Literature DB >> 8798460

Binding of A/T-rich DNA by three high mobility group-like domains in c-Abl tyrosine kinase.

Y J Miao1, J Y Wang.   

Abstract

The c-Abl tyrosine kinase has been shown previously to bind DNA. Using polymerase chain reaction-based binding site-selection methods, no consensus high affinity binding site for c-Abl was found. Instead, oligonucleotides with runs of A/T sequences were isolated, and purified c-Abl was shown to bind A/T-containing oligonucleotides better than those without A/T sequences. DNA binding of c-Abl was dependent on three high mobility group 1-like boxes (HLBs), which bound cooperatively to the A/T-rich oligonucleotides. To distinguish binding to A/T sequences per se from binding to nonspecific DNA with a bend at the A/T-rich region, two oligonucleotides were compared for binding to c-Abl. Both oligonucleotides contained A/T sequences. In one, the A/T motif was part of an 80-mer duplex DNA. In another, the A/T motif was in the duplex arm of an 80-mer "bubble DNA" containing an internal unpaired 20-mer region to provide a flexible hinge. Interestingly, the HLBs of c-Abl bound better to the oligonucleotide containing the bubble, suggesting a higher affinity for bent DNA rather than A/T sequences per se. Taken together, these observations define a new class of DNA binding domains, the HLBs, which do not bind DNA with a high degree of sequence specificity, but may selectively bind to bent DNA or to sequences that are easier to distort.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8798460     DOI: 10.1074/jbc.271.37.22823

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  Two distinct phosphorylation pathways have additive effects on Abl family kinase activation.

Authors:  Keith Q Tanis; Darren Veach; Henry S Duewel; William G Bornmann; Anthony J Koleske
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

2.  Promoter upstream bent DNA activates the transcription of the Clostridium perfringens phospholipase C gene in a low temperature-dependent manner.

Authors:  S Katayama; O Matsushita; C M Jung; J Minami; A Okabe
Journal:  EMBO J       Date:  1999-06-15       Impact factor: 11.598

Review 3.  ABL tyrosine kinases: evolution of function, regulation, and specificity.

Authors:  John Colicelli
Journal:  Sci Signal       Date:  2010-09-14       Impact factor: 8.192

4.  The amphiphysin-like protein 1 (ALP1) interacts functionally with the cABL tyrosine kinase and may play a role in cytoskeletal regulation.

Authors:  L Kadlec; A M Pendergast
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

Review 5.  Abl tyrosine kinases in T-cell signaling.

Authors:  Jing Jin Gu; Jae Ryun Ryu; Ann Marie Pendergast
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

Review 6.  The capable ABL: what is its biological function?

Authors:  Jean Y J Wang
Journal:  Mol Cell Biol       Date:  2014-01-13       Impact factor: 4.272

7.  Regulation of cell migration and morphogenesis by Abl-family kinases: emerging mechanisms and physiological contexts.

Authors:  William D Bradley; Anthony J Koleske
Journal:  J Cell Sci       Date:  2009-10-01       Impact factor: 5.285

8.  Multidomain targeting of Bcr-Abl by disruption of oligomerization and tyrosine kinase inhibition: toward eradication of CML.

Authors:  Geoffrey D Miller; David W Woessner; Monika J Sirch; Carol S Lim
Journal:  Mol Pharm       Date:  2013-08-20       Impact factor: 4.939

9.  Direct interaction of Jak1 and v-Abl is required for v-Abl-induced activation of STATs and proliferation.

Authors:  N N Danial; J A Losman; T Lu; N Yip; K Krishnan; J Krolewski; S P Goff; J Y Wang; P B Rothman
Journal:  Mol Cell Biol       Date:  1998-11       Impact factor: 4.272

10.  Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase.

Authors:  S Taagepera; D McDonald; J E Loeb; L L Whitaker; A K McElroy; J Y Wang; T J Hope
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.